# Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)

> **NCT04770064** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Austin V Stone**

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** High-dose/short-duration Fisetin
- **DRUG:** Low-dose/sustained-duration Fisetin
- **OTHER:** Oral placebo capsule

## Key facts

- **NCT ID:** NCT04770064
- **Lead sponsor:** Austin V Stone
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding was not awarded
- **Last updated:** 2022-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04770064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04770064, "Targeting Senescence to Reduce Osteoarthritis Pain and cartilagE Breakdown (ROPE)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04770064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*